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Purpose/Objective: The assessment of the procedure safety in 
Intraoperative Radiotherapy (IORT) with mobile machines analyzes the 
risk of using the dedicated equipments and the misunderstandings in 
work flows. This procedures optimization should led to a prospective 
analysis and errors management that helps to identify potential 
failure modes and severity of the clinical consequences on patients. 
Aim of this experience is to review the Intraoperative Radiation 
Therapy process with the mobile linear accelerator Novac7, applying 
the Failure Mode and Effects Analysis (FMEA) to improve patients 
safety.  
Materials and Methods: The FMEA analysis provides a systematic 
method for finding vulnerabilities in a process before they result in an 
error. Three steps were identified: 1) process study with involved 
phases and activities; 2) hazard analysis with identification of possible 
failure modes and their effects, calculating for each failure mode the 
risk probability number(RPN) by the product of three scores (severity, 
frequency and detectability of that failure, each on a scale of 1 to 
10); 3) planning additional safety measures scored for effectiveness (1 
to 10) and feasibility (1 to 10). The RPN scores can span a range of 1 
to 1000; decisions are made based on the RPN values. The RPN value 
less than 125 was considered of little concern of risk. 
Results: The FMEA analysis was tested on breast cancer patients 
treated with IORT in our centre from 2005 on. The procedure was 
examined in a multidisciplinary view. With regard to a medical 
perspective the main reported clinical risks were in patient’s 
identification, indication to treat and timing with other therapies. In 
our experience the use of standardized protocols and a good informed 
consent modality, shared between surgeon and radiotherapist, was 
able to reduce the risk and was a simple way to implement the 
results. The dose prescription, consisting of the volume to be treated, 
the used technique, the dose, energy and organs at risk (OAR) 
identification were checked with a written list and a double control, 
shared between physicist and radiotherapist, was performed. 
Technically each point of IORT was described and a report of the 
procedure was always inserted in the medical chart and into the 
software dedicated to Radiotherapy Department. Physical critical 
failure modes were identified as incorrect data entry at treatment 
console and underestimation of CTV extension, resulting in wrong dose 
distribution and CTV under-dosage. Several safety solutions were 
proposed, including in vivo dosimetry. 
Conclusions: FMEA is a widely-used tool for improving safety and can 
be easily adapted for IORT optimization. New risk management 
strategies can provide highly qualified procedures for avoiding the 
increase in acute and late toxicity and in the reduction of tumor 
control. The impact of this tool is under study.  
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Purpose/Objective: There is no consensus on boost target volume 
delineation in conserved breast in locally advanced breast cancer 
(LABC) after neoadjuvant chemotherapy (NACT). Inclusion of 
prechemotherapy target volume has the disadvantage of large 
volumes which will have a detrimental effect on cosmesis. Inclusion of 
postchemotherapy target volume has the advantage of smaller target 
volume but there could be a higher risk of recurrence.We therefore 
did a retrospective analysis of LABC patients who underwent breast 
conservation (BCS) after NACT to assess whether post NACT target 
volumes are adequate for achieving local control. 
Materials and Methods: Patients of LABC who underwent BCS and 
radiotherapy after NACT, registered between 2007-2011 were the 
subject of our analysis. After BCS,patients received whole breast and 
supraclavicular radiotherapy (50Gy/25 fractions/5wk or 42.4Gy/16# / 
3 wk) which was followed by boost (10-16Gy/5-8#/1-1.5wk). After 
evaluating patterns of recurrence in these patients, the information 
on lumpectomy specimen size, method of estimating tumour boost 
field size (whether based on visible scar, tumour cavity on CT scan, 
prechemotherapy tumour size or postchemotherapy tumour size) was 
sought to gain an insight on whether these had an impact on the local 
recurrence. 
Results: 43 patients were the subject of this analysis. The median age 
was 47 years,42% were premenopausal and 58% were postmenopausal. 
Histopathological subtypes were luminal A (23%), luminal B (23%), Her- 
2 type(14%) and basal type (40%). (47.7%)patients had stage II 
disease,12 (27.2%) had III A and 10 (22.7%) had IIIB disease at 
presentation. After NACT 33.3% patients acheived CR (complete 
response), 54.8% PR (partial response) and 11.8% had SD (stable 
disease). The surgical margins around tumour in lumpectomy 
specimens were based on pre-chemotherapy tumour size in all 
patients. Radiotherapy planning scan revealed tumour cavity in 33 
patients and clips in 19 patients. Boost target delineation was based 
on visible scar: 4 patients ( 9.7%), tumour cavity: 5 patients (12.1%), 
prechemotherapy target volume : 5 patients (12.1%) and post 
chemotherapy target volume:27 patients (65%). 2 patients did not 
receive a boost. At a median followup of 27.2 months (4-71 
months),no patient had ipsilateral breast tumour recurrence (IBTR), 
one patient had ipsilateral axillary node recurrence and four patients 
had distant metastases. 
Conclusions: Postchemotherapy target volume seems to be safe as 
boost volume delineation for radiotherapy in patients with LABC who 
undergo BCS after NACT. 
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Purpose/Objective: To assess the comparative effectiveness of 
traditional (normal-dose) and reductional (low-dose) variants of 
postmastectomy chest-wall irradiation with the criteria of local 
control, overall and relapse-free survival rates, frequency of 
postradiation cardiac complications. 
Materials and Methods: Two groups of patients with breast cancer IIB 
– IIIB stages were studied: the 1st group – variant of normal-dose (50 
Gy to chest wall in 25fractions) radiation therapy with/without 
chemotherapy (129 patients), the 2nd group – variant of low-dose (40 
Gy to chest wall in 20 fractions) radiation therapy with/without 
chemotherapy (82 patients). In all cases radiation therapy followed 
Madden mastectomy. Dose to regional areas (46-50 Gy according to 
the number of metastatic lymphatic nodes) as well as neoadjuvant 
and adjuvant chemotherapy regimes was similar in both groups. The 
median follow-up was 111 and 95 months for the 1st and 2nd group 
respectively. 
Results: Frequency of 5-year actuarial local-regional progression in 
case of normal-dose and low-dose variants was estimated as 6,2±2,1% 
and 3,7±2,1% respectively (p=0,4). Metastases developed in 34,6±4,2% 
and 19,5±4,4% of patients in the 1st and 2nd group (p<0,05). 5-year 
relapse-free survival was53,5±5,4% and 71,5.±6,4% and overall survival 
- 65,3±5,6% and 72,2±6,3% for the 1 and 2 group respectively (?=0,08). 
Late failure in ECG in patients with left-side chest-wall irradiation 
were detected in 55±11,1% in the low-dose group comparing to 
75±9,7% in the normal-dose group (?<0,05). 
Conclusions: There are no statistically significant differences in local 
control, overall and relapse-free survival rates of traditional normal-
dose and low-dose variants of postmastectomy chest-wall irradiation. 
This method of dose-reduced postmastectomy chest-wall irradiation in 
compliance with modern systemic treatment allows to decline risk of 
cardiotoxicity with the maintenance of the treatment effectiveness 
achieved by using traditional method. 
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Purpose/Objective: The aim of our report – to compare the results of 
different regimes of whole-breast irradiation (accelerated 
hypofractionated, dynamic hypofractionated and, standard radiation 
treatment) following breast-conserving surgery for breast cancer I-IIA 
stages. 
Materials and Methods: From 2000 till 2005 yy 333 patients aged R54 
years received whole-breast irradiation following breast-conserving 
surgery (lumpectomy + axillary and internal lymphatic dissection). The 
most commonly seen invasive ductal carcinoma (55%), the rare - 
Invasive lobular carcinoma (27%), Invasive ductal cancer with 
extensive in situ component (3%) and special forms (15%). Metastasis 
in ipsilateral axillary lymph nodes fixed in 17,4% cases. All patients 
received whole-breast irradiation with different regimens RT: 1 group 
- accelerated hypofractionated (3Gy per fraction over 2,5 weeks, total 
dose of 39Gy, N=112), 2 group – dynamic hypofractionated (5Gy per 
fraction - 2, then 2,5 per fraction - 15, over 3,5 weeks, total dose of 
47,5Gy, N=130) and 3 group - standard radiation treatment (2 Gy per 
fraction over 5 weeks, total dose of 45–50 Gy, N=91). We used three-
dimensional CT-based treatment planning, two traditional tangent 
radiotherapy fields 6-18 MV, changing the gantry angle, collimator 
angle, blocks to result in coverage of the breast while excluding the 
heart from the treatment fields and minimized dose to the lung. Local 
relapse: 0% (1 group), 0,9% (2 and 3 groups) at 5 years. Five-year 
